POXEL news, videos and press releases
For more news please use our advanced search feature.
POXEL - More news...
POXEL - More news...
- Poxel Announces Upcoming Participation at the H.C. Wainwright 2nd Annual Kidney Conference
- Poxel, winner of the 2023 edition of the I-nov contest
- Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris
- Poxel Announces Results from June 21, 2023 Ordinary Annual and Extraordinary General Meeting
- Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy
- Poxel Reports Cash and Revenue for the First Quarter 2023 and Provides Corporate Update
- Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023
- Poxel Announces TWYMEEG® (Imeglimin) Fiscal Year 2022 Sales
- Poxel Announces Upcoming Participation at the JMP Securities Life Science Conference
- Poxel Announces Availability of the 2022 Universal Registration Document and Provides Update on Accounts Settlement
- Poxel Announces Multiple TWYMEEG® (Imeglimin) Abstracts Accepted for Oral Presentation
- Poxel Announces Cash Runway Extended Through Q2 2025 Based upon Debt Restructuring Agreement and New Equity-linked Financing Facility
- Poxel Reports Financial Results for Full Year 2022 and Provides Corporate Update
- Poxel will Report its 2022 Full Year Results on March 23, 2023
- Poxel to Report its 2022 Full Year Results by the End of March 2023
- Poxel Announces Upcoming Participation at Evercore ISI’s NASH Renaissance Event
- Poxel Announces Publication of Positive Phase 2 Results from Phase 2 NASH Trial (DESTINY-1) for PXL065 in Journal of Hepatology
- Poxel Announces Publication in Kidney International of PXL770 Preclinical Results in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Poxel Reports Cash and Revenue for the Full Year 2022 and Provides Corporate Update
- Poxel Receives Orphan Drug Designation from the European Commission for PXL770 and PXL065 for Treatment of Adrenoleukodystrophy
- Poxel Announces Upcoming Participation at Investor Conferences
- Poxel Announces its Financial Calendar for 2023
- Poxel Announces Drawdown of the Remaining Two Tranches of its Equity-linked Financing Facility and Provides Corporate Update
- Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2022
- Poxel Announces Upcoming Participation at the Jefferies London Healthcare Conference
- Poxel Announces Upcoming Presentation at the H.C. Wainwright 6th Annual NASH Investor Virtual Conference
- Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022
- Availability of Poxel's 2022 Half-Year Financial Report
- Poxel Announces PXL770 Granted Orphan Drug Designation from the U.S. FDA for Autosomal-Dominant Polycystic Kidney Disease (ADPKD)
- Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized R-stereoisomer of Pioglitazone
